Drugs / Oral Iron
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy3 trials | ||||||
| Phase 3 | NCT05225545 Comparator | Nov 2019 → May 2024 | iron deficiency anemia, ulcerative colitis | American University of Beirut Medical Center | Unknown | No outcome recorded |
| Phase 3 | NCT01155388 Comparator | Oct 2011 → Jun 2014 | chronic kidney disease, iron deficiency anemia | AMAG Pharmaceuticals, Inc. | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT05114278 Background | Jul 2022 | celiac disease | Assistance Publique - Hôpitaux de Paris | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Oral Iron | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01155388 ↗ |
| Route | Oral | “Participants will receive oral iron: 2.5 mg Fe/kg twice daily” NCT01155388 ↗ |